TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25241958

Group type: EXPERIMENTAL
Intervention: e‐Re‐Know intervention (e-feedback knowledge of radiotherapy)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard education (control group)
Number of subjects: 126
Study: 23702610

Group type: EXPERIMENTAL
Intervention: Ahmed valve implant surgery with combined short scleral tunnel with Tenon advancement and duplication technique
Number of subjects: 276

Group type: COMPARATOR
Intervention: AGV implant surgery without patch graft
Number of subjects: 276

Group type: COMPARATOR
Intervention: AGV implant surgery with donor scleral patch
Number of subjects: 276
Study: 21388309

Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg once daily)
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4447

Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 4447
Study: 19930508

Group type: EXPERIMENTAL
Intervention: Repeated testing (SE-T/MG-S group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Repeated study (MG-T/SE-S group)
Number of subjects: 40
Study: 16368389

Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Surgery (LVRS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Best Medical Care (BMC)
Number of subjects: 62
Study: 15320662

Group type: EXPERIMENTAL
Intervention: 1-minute rest interval
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2-minute rest interval
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3-minute rest interval
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 11298707

Group type: EXPERIMENTAL
Intervention: 800 nm scanning diode laser at 48 J/cm2
Number of subjects: 36

Group type: COMPARATOR
Intervention: 800 nm scanning diode laser at 24, 38, or 48 J/cm2
Number of subjects: 36
Study: 9260068

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5, 1.0, and 2.0 g/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pentobarbital (150, 300, 600, and 750 mg/70 kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7644443

Group type: EXPERIMENTAL
Intervention: Predisposing factors (beliefs, perceived benefits, and motivation)
Number of subjects: 16287

Group type: COMPARATOR
Intervention: Enabling factors (barriers, norms, and social support)
Number of subjects: 16287
Study: 2501383

Group type: EXPERIMENTAL
Intervention: Oral dextroamphetamine 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 81190

Group type: EXPERIMENTAL
Intervention: Regimen B (BACON combination, slightly modified)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Regimen A (adriamycin plus cyclophosphamide)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Regimen CVP (cyclophosphamide plus vincristine plus prednisone)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Supportive treatment
Number of subjects: 32
Study: 28452960

Group type: EXPERIMENTAL
Intervention: 200 mg per day Pycnogenol® (P+)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No treatment (Co)
Number of subjects: 33
Study: 26035682

Group type: EXPERIMENTAL
Intervention: Dorsiflexed (DF) position stretching
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Plantar-flexed (PF) position stretching
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no stretching)
Number of subjects: 34
Study: 24306695

Group type: EXPERIMENTAL
Intervention: 1.0 mg/mL rhBMP-2/CPM
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: 2.0 mg/mL rhBMP-2/CPM
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Buffer/CPM
Number of subjects: 369

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 369
Study: 21880996

Group type: EXPERIMENTAL
Intervention: Cortical stimulation
Number of subjects: 60
Study: 19836626

Group type: EXPERIMENTAL
Intervention: ALA (400mg/day)
Number of subjects: 14
Study: 17099012

Group type: EXPERIMENTAL
Intervention: Zolpidem (oral hypnotic agent)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard care (neither zolpidem nor placebo)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All groups (Zolpidem, Placebo, Standard Care)
Number of subjects: 72
Study: 15640625

Group type: EXPERIMENTAL
Intervention: Instructions from a standardized patient to military healthcare providers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11720425

Group type: EXPERIMENTAL
Intervention: 5FU plus levamisole
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Observation (no further treatment)
Number of subjects: 1029
Study: 8907804

Group type: EXPERIMENTAL
Intervention: Indobufen [200 mg orally twice daily (p.o. b.i.d.) for a week]
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1685875

Group type: EXPERIMENTAL
Intervention: 1 mg lormetazepam alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1 mg lormetazepam with 200 mg cimetidine
Number of subjects: 10
Study: 6416513

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 103

Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 103
Study: 31266826

Group type: EXPERIMENTAL
Intervention: Low glycemic load (GL) diet high in whole grains, legumes, fruits, and vegetables (WG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: High glycemic load (GL) diet high in refined grains and added sugars (RG)
Number of subjects: 80
Study: 28465460

Group type: EXPERIMENTAL
Intervention: tPA + stentriever thrombectomy
Number of subjects: 173

Group type: COMPARATOR
Intervention: tPA alone
Number of subjects: 173
Study: 25402429

Group type: EXPERIMENTAL
Intervention: 2% M. hamburg grape seed extract formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (base)
Number of subjects: 0
Study: 25037002

Group type: EXPERIMENTAL
Intervention: Therapeutic group (TG) rehabilitation interventions
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both groups (TG and CG)
Number of subjects: 165
Study: 22658389

Group type: EXPERIMENTAL
Intervention: 22G FNA
Number of subjects: 56

Group type: COMPARATOR
Intervention: 22G FNB
Number of subjects: 56
Study: 19734628

Group type: EXPERIMENTAL
Intervention: Octreotide LAR (O‐LAR)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Octreotide short‐acting (O‐SA)
Number of subjects: 7
Study: 17634482

Group type: EXPERIMENTAL
Intervention: AZD2171 (0.5 to 60 mg, once-daily)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: AZD2171 (20, 30, or 45 mg, once-daily)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: AZD2171 (once-daily)
Number of subjects: 83
Study: 15459209

Group type: EXPERIMENTAL
Intervention: Baseline health‐related quality of life (HRQOL) parameters assessed by the EORTC QLQ‐C30
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Model including HRQOL factors
Number of subjects: 391

Group type: COMPARATOR
Intervention: Model without HRQOL factors
Number of subjects: 391
Study: 12397471

Group type: EXPERIMENTAL
Intervention: Brain perfusion SPET with PVE correction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Brain perfusion SPET without PVE correction
Number of subjects: 30
Study: 9817092

Group type: EXPERIMENTAL
Intervention: Ultrasound detection of renal scarring
Number of subjects: 339

Group type: COMPARATOR
Intervention: DMSA scintigraphy
Number of subjects: 339
Study: 7535040

Group type: COMPARATOR
Intervention: Single-donor plateletpheresis concentrates (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (6 x 10(6) KIU) (Group B)
Number of subjects: 40
Study: 14589683

Group type: EXPERIMENTAL
Intervention: Attending to the signal while shadowing the story (Experiment 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Did not shadow the story (Experiment 2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal controls (both experiments)
Number of subjects: 48
Study: 155391

Group type: EXPERIMENTAL
Intervention: Locetamic acid (Cholebrine)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Ipodate sodium (Oragrafin)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Both contrast agents
Number of subjects: 503
Study: 31765643

Group type: EXPERIMENTAL
Intervention: Pubovisceral muscle tear
Number of subjects: 56

Group type: COMPARATOR
Intervention: No pubovisceral muscle tear
Number of subjects: 56
Study: 30472123

Group type: EXPERIMENTAL
Intervention: 800 mg IV ibuprofen in 100 mL saline
Number of subjects: 40

Group type: COMPARATOR
Intervention: 100 mL saline solution
Number of subjects: 40
Study: 28283286

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion plus supportive care (4 units of pooled platelets given daily when platelet count was 20,000 per μL or lower)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion plus supportive care
Number of subjects: 372
Study: 26013860

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery (HALS)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Conventional open surgery (COS)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 291
Study: 23672966

Group type: EXPERIMENTAL
Intervention: Hormonal contraception (HC+)
Number of subjects: 209
Study: 21429018

Group type: EXPERIMENTAL
Intervention: Silicone PEG tubes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Latex PEG tubes
Number of subjects: 60
Study: 19623149

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol plus ipratropium bromide
Number of subjects: 60

Group type: COMPARATOR
Intervention: L‐adrenaline
Number of subjects: 60
Study: 17316372

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15212350

Group type: EXPERIMENTAL
Intervention: 81 mg aspirin
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 325 mg aspirin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 11599649

Group type: EXPERIMENTAL
Intervention: 90-mg weekly enteric-coated fluoxetine
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: 20-mg daily fluoxetine
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study: 9144027

Group type: EXPERIMENTAL
Intervention: IgG myeloma proteins
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 stimulated natural killer cells
Number of subjects: 118

Group type: COMPARATOR
Intervention: Natural killer cell activity in multiple myeloma patients
Number of subjects: 118

Group type: COMPARATOR
Intervention: Natural killer cell number
Number of subjects: 118
Study: 8194326

Group type: EXPERIMENTAL
Intervention: Preoperative teaching done on a preadmission basis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative teaching done on a postadmission basis
Number of subjects: 0
Study: 2831788

Group type: EXPERIMENTAL
Intervention: Enalapril (10‐20 mg) with hydrochlorothiazide plus amiloride
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Timolol (10‐20 mg) with hydrochlorothiazide plus amiloride
Number of subjects: 59
Study: 29950166

Group type: EXPERIMENTAL
Intervention: Occupational advice intervention to facilitate return to work and usual activities
Number of subjects: 0
Study: 27267965

Group type: EXPERIMENTAL
Intervention: Specialist-taught PE program (2×45 min lessons/week for 4 years)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Specialist-taught PE program
Number of subjects: 853
Study: 25710802

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3883

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3883
Study: 22099039

Group type: EXPERIMENTAL
Intervention: Magnesium oxide (500 mg twice a day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 19130636

Group type: EXPERIMENTAL
Intervention: Nonperiodized (NP) training program
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Traditional periodized linear (PL) training program
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Planned nonlinear periodized (PNL) training program
Number of subjects: 51
Study: 17128436

Group type: EXPERIMENTAL
Intervention: Harpagophytum procumbens (Devil's Claw)
Number of subjects: 0
Study: 15016559

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% ophthalmic solution QD (n=38)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% ophthalmic solution QD (n=38)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Timolol gel-forming ophthalmic solution 0.5% QD (n=39)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Bimatoprost and Latanoprost (both QD)
Number of subjects: 115
Study: 12516489

Group type: COMPARATOR
Intervention: Diclofenac 1 mg/Kg i.m. 60 minutes before surgery and continuous infusion of 1.5 mg/Kg over 24 hours (DD)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diclofenac 1 mg/Kg i.m. 60 minutes before surgery and infused saline solution after extubation (DP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo before surgery and diclofenac afterwards (PD)
Number of subjects: 90
Study: 9690730

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole o.m. plus amoxycillin 1000 mg b.d. plus clarithromycin 500 mg b.d. (O20AC500)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole o.m. plus amoxycillin 1000 mg b.d. plus clarithromycin 1000 mg b.d. (O20AC1000)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole b.d. plus amoxycillin 1000 mg b.d. plus clarithromycin 500 mg b.d. (O40AC500)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole b.d. plus amoxycillin 1000 mg b.d. plus clarithromycin 1000 mg b.d. (O40AC1000)
Number of subjects: 274
Study: 7864315

Group type: EXPERIMENTAL
Intervention: Epidural administration of alfentanil (1 mg followed by 0.2 mg.h-1 infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (sodium chloride via sham catheter)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epidural administration of alfentanil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 2817661

Group type: EXPERIMENTAL
Intervention: Tropicamide 0.05% combined with hydroxyamphetamine 1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tropicamide 0.1% combined with hydroxyamphetamine 1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tropicamide 0.25% combined with hydroxyamphetamine 1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tropicamide 0.5% combined with hydroxyamphetamine 1%
Number of subjects: 0
Study: 1081905

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with 1 chemotherapy agent
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with 2 chemotherapy agents
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with 3 chemotherapy agents
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with 4 chemotherapy agents
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with 3 drugs plus supplemental chemotherapy or irradiation (special categories)
Number of subjects: 149
Study: 30611756

Group type: EXPERIMENTAL
Intervention: Real tDCS (2 mA, anode right/cathode left targeting the dorsolateral prefrontal cortex for 20 min)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham tDCS (only for the first and last minute)
Number of subjects: 74
Study: 29423663

Group type: EXPERIMENTAL
Intervention: Resistive pulse sensing (RPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dynamic light scattering (DLS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Size-exclusion chromatography with in-line multi-angle light scattering (SEC-MALS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo formulations spiked with silicone oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein formulations stressed via freeze-thaw cycling, thermal incubation, and acid treatment
Number of subjects: 0
Study: 27150493

Group type: EXPERIMENTAL
Intervention: Intervention group (showing the larger historical Heartmate XVE before the HMII)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Control group (only shown the HMII device)
Number of subjects: 487
Study: 24482301

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg or 90 mg at week 0, week 4, q12 weeks
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg or 90 mg
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 22677045

Group type: EXPERIMENTAL
Intervention: Subcutaneous ixekizumab (5, 15, 50, or 150 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subcutaneous ixekizumab
Number of subjects: 40
Study: 20016250

Group type: EXPERIMENTAL
Intervention: Silver textiles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo textiles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine-based washing at 60 degrees C
Number of subjects: 0
Study: 17322427

Group type: EXPERIMENTAL
Intervention: Total hip replacement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bipolar hemiarthroplasty
Number of subjects: 120
Study: 16364049

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg intravenously infused over 10, 15, 20, or 30 minutes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg intravenously as an injection over 3 minutes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Esomeprazole (both dosages)
Number of subjects: 24
Study: 12063585

Group type: EXPERIMENTAL
Intervention: Acupuncture YNSA basis-point D
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acupuncture at the classical point Xiao Chang Shu = Bl 27
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo point of the head
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo point of the gluteal region
Number of subjects: 42
Study: 9598622

Group type: EXPERIMENTAL
Intervention: 1.2 g co-amoxiclav intravenously followed by three further doses of oral co-amoxiclav (Group 1)
Number of subjects: 83

Group type: COMPARATOR
Intervention: 1.2 g co-amoxiclav intravenously (Group 2)
Number of subjects: 83
Study: 7712689

Group type: EXPERIMENTAL
Intervention: Endurance training alone (n = 18)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Endurance training in combination with selected resistance exercises (n = 17)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-exercising control group (n = 9)
Number of subjects: 44
Study: 2472988

Group type: EXPERIMENTAL
Intervention: 10 mg of pirenzepine (PZ) intravenously every 12 hours
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 20 mg of pirenzepine (PZ) intravenously every 12 hours
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no pirenzepine)
Number of subjects: 115
Study: 309031

Group type: EXPERIMENTAL
Intervention: Cold cardioplegic method (Group A) - 4 degrees C. asanguineous solution with 30 mEq. of potassium per liter infused into the aortic root for about 2 minutes after aortic cross-clamping and again after 45 minutes or when myocardial temperature rose above 19 degrees C.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Simple cardiac cooling by hypothermic systemic perfusion before aortic cross-clamping plus external cardiac cooling (Group B).
Number of subjects: 34
Study: 31651605

Group type: EXPERIMENTAL
Intervention: Mine workers
Number of subjects: 1169

Group type: COMPARATOR
Intervention: General population
Number of subjects: 1169
Study: 28113105

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for stuttering (7-day duration)
Number of subjects: 39
Study: 25842727

Group type: EXPERIMENTAL
Intervention: Intervention and oral administration of Chinese medicine (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intervention alone (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral administration of Chinese medicine only (Group C)
Number of subjects: 90
Study: 23926681

Group type: EXPERIMENTAL
Intervention: Low-dose testosterone undecanoate capsules combined with tadalafil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tadalafil
Number of subjects: 90
Study: 21842020

Group type: EXPERIMENTAL
Intervention: Medium toothbrushes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Soft toothbrushes
Number of subjects: 25
Study: 19894377

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus Fluoxetine
Number of subjects: 95
Study: 17444512

Group type: EXPERIMENTAL
Intervention: Early screening
Number of subjects: 351

Group type: COMPARATOR
Intervention: Traditional external review
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 351
Study: 14991552

Group type: EXPERIMENTAL
Intervention: 3-month ankle-strengthening and walking program
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 12566672

Group type: EXPERIMENTAL
Intervention: Venous cuff interposition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no venous cuff)
Number of subjects: 40
Study: 9821903

Group type: EXPERIMENTAL
Intervention: High-dose laser therapy (5J/cm2)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Low-dose laser therapy (0.5J/cm2)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo laser therapy (0J/cm2)
Number of subjects: 217
Study: 8021909

Group type: EXPERIMENTAL
Intervention: Nebivolol (1, 5, or 10 mg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) (12.5 mg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) (25 mg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combination of nebivolol and HCTZ
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 2738226

Group type: EXPERIMENTAL
Intervention: Nursing unit with therapeutic nursing focus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acute hospital wards
Number of subjects: 0
Study: 4555654

Group type: EXPERIMENTAL
Intervention: Trimethoprim
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 339
Study: 31376435

Group type: EXPERIMENTAL
Intervention: Topical Thrombin (Human) Grifols (TTH-Grifols)
Number of subjects: 205